[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of 943 shares of the issuer's common stock on 08/27/2025 to satisfy tax withholding related to restricted stock units that vested from a grant made on 02/26/2024. The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, with a reported weighted-average sale price of $21.4847. After the reported sale, the reporting person beneficially owned 958,148 shares directly. The Form 4 was signed by an attorney-in-fact, Paul Kim, on 08/28/2025. No derivative transactions or other amendments are disclosed in this filing.

Positive

• Transparent disclosure of the reason for the sale (tax-withholding on vested RSUs) and the original grant date.
• Small disposition relative to holdings: only 943 shares sold versus 958,148 shares retained, indicating continued ownership alignment.
• Price-range provided ($21.28–$21.66) and weighted-average sale price reported ($21.4847).

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider sale was a tax-withholding sell-to-cover of vested RSUs; the executive retains a large direct stake.

The filing shows a routine sell-to-cover transaction tied to the vesting of restricted stock units granted on 02/26/2024. The number sold (943 shares) is immaterial relative to the reported post-transaction holding (958,148 shares), indicating no change in control or significant cashing out by the officer. The weighted-average price reported is $21.4847, with transaction prices disclosed between $21.28 and $21.66. The use of an attorney-in-fact signature is common for administrative filings. From an investor-impact perspective, this is a non-material, administrative disposition.

Corporate Governance Expert

TL;DR: Transaction consistent with standard tax-withholding practice; no governance red flags evident.

The sale is explicitly described as occurring to satisfy tax withholding obligations from vested RSUs. The Form 4 discloses the original grant date and references the prior Form 4 reporting the grant, which supports transparency. There are no indications of unusual timing, large-scale disposition, or related-party transactions. Beneficial ownership remains substantial at 958,148 shares, suggesting continued alignment with shareholder interests. Documentation and price-range disclosure meet typical disclosure expectations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		S		943(1)	D	$21.4847(2)	958,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.

2. The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

	/s/ Paul Kim as Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FLGT insider Gao Hanlin do on 08/27/2025?

The reporting person sold 943 shares of Fulgent Genetics common stock on 08/27/2025 to satisfy tax withholding for vested RSUs.

Why were the FLGT shares sold by Gao Hanlin?

The shares were sold to satisfy tax withholding obligations that arose when restricted stock units granted on 02/26/2024 vested.

At what price were the FLGT shares sold?

Sales occurred at prices ranging from $21.28 to $21.66; the reported weighted-average sale price was $21.4847.

How many FLGT shares does Gao Hanlin own after the sale?

After the transaction the reporting person beneficially owned 958,148 shares directly.

Who signed the Form 4 for Gao Hanlin?

The Form 4 was signed by Paul Kim as attorney-in-fact on 08/28/2025.